EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of Real-World Vancomycin Dosing and Attainment of Therapeutic Drug Monitoring Targets

Nicole Bradley iD, Kimberly Ng

Pharmacy · 06.06.2023 · 11 (3) · 95

DOI: 10.3390/pharmacy11030095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacy, online erschienen am 06.06.2023. Verfasst von Nicole Bradley und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In 2020, the Infectious Diseases Society of America (IDSA) recommended a change in vancomycin therapeutic drug monitoring from trough-based to AUC/MIC-based to optimize vancomycin’s efficacy and reduce nephrotoxicity. Many hospitals have not implemented this change due to barriers such as the cost of AUC/MIC software and lack of provider familiarity. The purpose of this study was to determine the rate of AUC/MIC ratio target attainment using current trough-based vancomycin dosing practices at a city hospital. The rates of acute kidney injury (AKI) were also evaluated. Vancomycin orders were reviewed retrospectively to determine the expected AUC/MIC ratios using first-order pharmacokinetic equations over a 7-month period. Orders were excluded if they were written for a one-time dose, for individuals less than 18 years of age, or for those on hemodialysis. A total of 305 vancomycin orders were included in this review. Overall, 27.9% (85/305) of vancomycin orders attained the AUC/MIC ratio target of 400–600 mg·h/L as recommended by the guidelines. Nearly 35% (106/305) achieved AUC/MIC ratios below 400 mg·h/L and 37.4% (114/305) achieved AUC/MIC ratios above 600 mg·h/L. Orders for obese patients were significantly more likely to have below the target AUC/MIC ratios (68% vs. 23.9%, X2 48.48, p < 0.00001) and non-obese patients were significantly more likely to have above the target AUC/MIC ratios (45.7% vs. 12%, X2 27.36, p < 0.00001). The overall rate of acute kidney injury observed was 2.6%. Most vancomycin orders did not attain therapeutic drug monitoring targets, reflecting the ongoing clinical challenge of optimizing vancomycin doses and implementing new guideline recommendations.

Schlagwörter

Stichwörter der Autor:innen

AUC/MIC ratiopharmacokineticstherapeutic drug monitoringvancomycin

Autor:innen und Institutionen

  • College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA.

ORCID-Profile: Nicole Bradley

Zitieren

APA

Bradley, N., & Ng, K. (2023). Evaluation of Real-World Vancomycin Dosing and Attainment of Therapeutic Drug Monitoring Targets. Pharmacy, 11(3), 95. https://doi.org/10.3390/pharmacy11030095

Vancouver

Bradley N, Ng K. Evaluation of Real-World Vancomycin Dosing and Attainment of Therapeutic Drug Monitoring Targets. Pharmacy. 2023;11(3):95. doi:10.3390/pharmacy11030095

BibTeX
@article{Bradley2023,
  author = {Bradley, Nicole and Ng, Kimberly},
  title = {Evaluation of Real-World Vancomycin Dosing and Attainment of Therapeutic Drug Monitoring Targets},
  journal = {Pharmacy},
  year = {2023},
  volume = {11},
  number = {3},
  pages = {95},
  doi = {10.3390/pharmacy11030095}
}
Kostenlos starten →